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INTRODUCTION {#jso24104-sec-0005}
============

Prognostic biomarkers are the most important instrument for tailoring oncologic treatment and predicting cancer patientś prognosis. In gastric cancer (GC), the tumor‐ (T), node‐ (N), metastasis‐ (M) classification of the union internationale contre le cancer (UICC) is the single currently used prognostic biomarker on a routine basis, but recent studies have shown that the 7th edition of the UICC‐stage grouping is not able to sufficiently discriminate patient\'s survival [1](#jso24104-bib-0001){ref-type="ref"}, [2](#jso24104-bib-0002){ref-type="ref"}, [3](#jso24104-bib-0003){ref-type="ref"}. Additional reliable prognostic biomarkers, for example, immunohistochemistry or RNA/DNA‐based tests, are urgently needed but not established yet on a routine basis [4](#jso24104-bib-0004){ref-type="ref"}.

The quest for a significant prognostic biomarker in GC has led to the examination of Ki67 over 20 years ago [5](#jso24104-bib-0005){ref-type="ref"}, [6](#jso24104-bib-0006){ref-type="ref"}, [7](#jso24104-bib-0007){ref-type="ref"}. Ki67 is a nuclear located protein that is closely linked to cell proliferation. It is present in all active phases of the cell cycle, but absent from resting cells, thus, indicating the proliferating cell fraction [8](#jso24104-bib-0008){ref-type="ref"}. Ki67 is an established prognostic biomarker in several tumor entities, for example, breast cancer, lymphoma, and neuroendocrine neoplasia [9](#jso24104-bib-0009){ref-type="ref"}, [10](#jso24104-bib-0010){ref-type="ref"}, [11](#jso24104-bib-0011){ref-type="ref"}. Despite several previous investigations, the prognostic value of Ki67 proliferation index (PI) in GC remains contradictious. Different analytical methods to assess the Ki67 PI were used, and former investigations mainly relied on tissue microarrays (TMAs) without ever evaluating whether TMAs are suitable in general for the determination of the Ki67 PI in GC.

In order to fill this gap of information, we systemically investigated the prognostic value of the Ki67 PI in a large and thoroughly characterized cohort of GC, testing the following hypothesis: (i) Does Ki67 show any distinct intratumoral expression pattern in whole tissue sections (WTS); (ii) is the detection of Ki67 PI influenced by sample age, (iii) are TMAs applicable in the determination of the Ki67 PI in GC; and (iv) is the Ki67 PI related to clinico‐pathological patient characteristics and/or prognostically relevant in GC.

MATERIALS AND METHODS {#jso24104-sec-0006}
=====================

Study Population {#jso24104-sec-0007}
----------------

From the archive of the Institute of Pathology, University Hospital Kiel, we sought caucasian patients who had undergone either total or partial gastrectomy for adenocarcinoma of the stomach or oesophago‐gastric junction between 1997 and 2009. The following patient characteristics were retrieved: type of surgery, age at diagnosis, gender, tumor size, tumor localization, tumor type, tumor grade, depth of invasion, residual tumor status, number of lymph nodes resected, and number of lymph nodes with metastases. Patients were included if: (i) an adenocarcinoma of the stomach or oesophago‐gastric junction was histologically confirmed; (ii) the overall tumor mass was large enough to get five TMA punches; and (iii) the Ki67 PI could be assigned on both WTS *and* corresponding TMAs obtained from the same paraffin blocks. Exclusion criteria were defined as: (i) histology identified a tumor type other than adenocarcinoma; and (ii) patients had undergone a perioperative chemo‐ or radiotherapy. Each resected specimen had undergone gross sectioning and histological examination by trained and board certified surgical pathologists. Date of patient death was obtained from the *Epidemiological Cancer Registry* of the state of Schleswig‐Holstein, Germany. Follow‐up data of those patients who were still alive were retrieved from hospital records and general practitioners. Ethical approval was obtained from the local ethical review board (D 453/10). All patient data were pseudonymized prior to study inclusion.

Histology {#jso24104-sec-0008}
---------

Tissue specimens were fixed in formalin and embedded in paraffin (FFPE). Deparaffinized sections were stained with hematoxylin and eosin. Histological re‐examination of primary tissue sections was carried out for all cases to assure if inclusion criteria were confirmed. Tumors were classified according to the Laurén classification [12](#jso24104-bib-0012){ref-type="ref"} and re‐examined by two surgical pathologists. pTNM‐stage of all study patients was determined according to the 7th edition of the UICC guidelines [13](#jso24104-bib-0013){ref-type="ref"}.

Tissue Microarray Construction {#jso24104-sec-0009}
------------------------------

FFPE tissue samples were used to generate TMAs as described previously [14](#jso24104-bib-0014){ref-type="ref"}. Briefly, five morphologically representative regions of the paraffin "donor" blocks (tumor) were chosen, and tissue cylinders of 1.5 mm diameter were punched from these areas. Afterwards, the tissue cylinders were inserted into a new "recipient" paraffin block using a custom‐built instrument (Beecher Instruments, Silver Spring, MD). The new recipient paraffin blocks were warmed in a 60°C heating cabinet for 7 min to create a sufficient bond between the tumor tissue and the recipient block paraffin. 2.5 μm thick serial sections were obtained from the new recipient paraffin blocks, dried in a 60°C heating cabinet for 6 hr and stored in polystyrene slide storage boxes at 8°C until use.

Immunohistochemistry, Assessment of Microsatellite Instability and Detection of *Helicobacter pylori*‐ and Epstein‐Barr‐Virus‐Infection {#jso24104-sec-0010}
---------------------------------------------------------------------------------------------------------------------------------------

Immunohistochemical stainings were carried out with a Bondmax (Leica Biosystems, Wetzlar, Germany) automated slide staining system, using the Polymer Refine Detection Kit (Menarini Diagnostics, Berlin, Germany) and a monoclonal rabbit antibody, directed against Ki67 (clone SP6, Abcam, Cambridge, United Kingdom). Pretreatment was done with ER2 for 20 min. The antibody was diluted in antibody diluent (Zytomed Systems, Berlin, Germany) and applied in a 1:300 dilution. Immunohistochemical stainings of Her2/neu, the assessment of microsatellite instability using immunohistochemistry and molecular biology, and the evaluation of *Helicobacter pylori*‐ and Epstein‐Barr‐virus‐infection was carried out as previously described [4](#jso24104-bib-0004){ref-type="ref"}, [15](#jso24104-bib-0015){ref-type="ref"}.

Evaluation of Immunostaining {#jso24104-sec-0011}
----------------------------

The nuclear expression of Ki67 was manually counted within 500 tumor cells for each tumor in the area of the highest density of Ki67‐positive nuclei ("hot spot"). All nuclear staining was considered as "positive," irrespective of its intensity. The Her2/neu status was assessed as previously described [15](#jso24104-bib-0015){ref-type="ref"}.

Study Design {#jso24104-sec-0012}
------------

In a first step, the Ki67 PI of each tumor was evaluated immunohistochemically on WTS and TMAs of corresponding tumors, and the level of agreement was assigned. The intralaboratory variability was studied by correlating the staining results of the WTS and TMAs with sample age. Additionally, the staining results of the WTS were correlated with clinico‐pathological characteristics, including gender, age, Laurén phenotype, mucin phenotype, localization, T‐ and N‐category, lymphatic invasion (L‐category), venous invasion (V‐category), UICC‐stage (7th edition), lymph node ratio (LNR), tumor grade, residual tumor status, *Helicobacter pylori‐*, Epstein‐Barr‐virus (EBV)‐, microsatellite instability (MSI)‐, and Her2/neu‐status, as well as survival data.

Statistical Analysis {#jso24104-sec-0013}
--------------------

Statistical analyses were done using SPSS 20.0 (IBM Corporation, New York). Ki67 raw values were correlated with clinico‐pathological patient characteristics and survival data. For comparison purposes, the Ki67 PI evaluated by WTS was dichotomized at the median; patients below median were classified as "Ki67 low," patients with a Ki67 PI ≥ median were classified as "Ki67 high." The Ki67 PI was split into quartiles additionally. Moreover, a subgroup analysis of intestinal‐ and diffuse‐type GCs according to the Laurén classification was done. The correlation between the Ki67 PI of WTS and TMAs was calculated by using Spearman\'s rho and Cohen\'s kappa. A kappa value of 0.20 was considered to be poor, of 0.21--0.40 to be fair, of 0.41--0.60 to be moderate, of 0.61--0.80 to be good, and of 0.81--1.00 to be very good. Median overall survival and tumor specific survival was determined using the Kaplan--Meier method, and the log‐rank test was used to determine significance. We further applied a Cox regression to calculate the influence of raw Ki67 PI on survival. The significance of correlation between clinico‐pathological parameters and the Ki67 PI groups evaluated by WTS was tested using Fisher\'s exact test. For parameters of ordinal scale (T‐category, N‐category, UICC stage) we applied Kendall\'s tau test instead. For the comparison between raw Ki67 PI values and clinico‐pathological characteristics we calculated median values and 25%‐ and 75%‐percentiles, respectively. Significance of differences between median values was assessed using the Kruskal‐Wallis test. *P* values were derived from two‐tailed tests. A *P* ≤ 0.05 was considered statistically significant. No adjustments were made. To account for the effects of multiple testing, we applied the explorative Simes (Benjamini‐Hochberg) procedure [16](#jso24104-bib-0016){ref-type="ref"}.

RESULTS {#jso24104-sec-0014}
=======

Three hundred and fifteen patients fulfilled all study criteria. The clinico‐pathological patient characteristics are summarized in Table [I](#jso24104-tbl-0001){ref-type="table-wrap"}. According to Laurén, an intestinal phenotype was found in 170 (54.0%), a diffuse type in 82 (26.0%), a mixed type in 23 (7.3%), and an unclassifiable type in 40 (12.7%) patients. Overall survival data was available in 304 of 315 cases (96.5%), tumor specific survival data in 281 of 315 cases (89.2%). Mean follow‐up period was 17.6 months (range 0.07--142.7 months).

###### 

Clinico‐Pathological Patient Characteristics and Correlation With the Ki67 Proliferation Index

                                                                                                 Raw Ki67 PI   Dichotomized Ki67 PI   Ki67 PI split into Quartiles                                                                                                                                                                 
  ------------------------------------ ---------------------------- --------------- ------------ ------------- ---------------------- ------------------------------------------------------- ------------ ------------ ------------------------------------------------------- ------------ ------------ ------------ ----------- -----------------------------------------------------
  Gender                               315                          Female          113 (35.9)   67            (41--82)               0.141[^a^](#jso24104-note-0003){ref-type="fn"}          60 (53.1)    53 (46.9)    0.412[^c^](#jso24104-note-0005){ref-type="fn"}          35 (31.0)    25 (22.1)    30 (26.5)    23 (20.4)   0.092[^d^](#jso24104-note-0006){ref-type="fn"}
                                       Male                         202 (64.1)      69           (51--84)                             97 (48.0)                                               105 (52.0)                43 (21.3)                                               54 (26.7)    49 (24.3)    56 (27.7)                
  Age                                  315                          ≤68 years       142 (46.6)   68            (45--83)               0.544[^a^](#jso24104-note-0003){ref-type="fn"}          72 (50.7)    70 (49.3)    1.000[^c^](#jso24104-note-0005){ref-type="fn"}          40 (28.2)    32 (22.5)    37 (26.1)    33 (23.2)   0.454[^d^](#jso24104-note-0006){ref-type="fn"}
                                       \>68 years                   163 (53.4)      69           (51--84)                             82 (50.3)                                               81 (49.7)                 37 (22.7)                                               45 (27.6)    37 (22.7)    44 (27.0)                
  Laurén phenotype                     315                          Intestinal      170 (54.0)   72            (55--85)               **\<0.001** [^a^](#jso24104-note-0003){ref-type="fn"}   70 (41.2)    100 (58.8)   **\<0.001** [^c^](#jso24104-note-0005){ref-type="fn"}   28 (16.5)    42 (24.7)    50 (29.4)    50 (29.4)   **0.004** [^c^](#jso24104-note-0005){ref-type="fn"}
                                       Diffuse                      82 (26.0)       52           (35--75)                             57 (69.5)                                               25 (30.5)                 35 (42.7)                                               22 (26.8)    13 (15.9)    12 (14.6)                
                                       Mixed                        23 (7.3)        72           (52--85)                             10 (43.5)                                               13 (56.5)                 5 (21.7)                                                5 (21.7)     6 (26.1)     7 (30.4)                 
                                       Unclassified                 40 (12.7)       69           (43--84)                             20 (50.0)                                               20 (50.0)                 10 (25.0)                                               10 (25.0)    10 (25.0)    10 (25.0)                
  Mucin phenotype                      279                          Intestinal      82 (29.4)    74            (52--84)               0.241[^a^](#jso24104-note-0003){ref-type="fn"}          33 (40.2)    49 (59.8)    0.221[^c^](#jso24104-note-0005){ref-type="fn"}          19 (23.2)    14 (17.1)    26 (31.7)    23 (28.0)   0.114[^c^](#jso24104-note-0005){ref-type="fn"}
                                       Gastric                      35 (12.5)       63           (40--80)                             18 (51.4)                                               17 (48.6)                 12 (34.3)                                               6 (17.1)     11 (31.4)    6 (17.1)                 
                                       Mixed                        117 (41.9)      68           (53--84)                             61 (52.1)                                               56 (47.9)                 25 (21.4)                                               36 (30.8)    24 (20.5)    32 (27.4)                
                                       Unclassified                 45 (16.1)       59           (46--78)                             26 (57.8)                                               19 (42.2)                 12 (26.7)                                               14 (31.1)    13 (28.9)    6 (13.3)                 
  Localization                         315                          Proximal        108 (34.3)   76            (58--86)               0.003[^a^](#jso24104-note-0003){ref-type="fn"}          43 (39.8)    65 (60.2)    0.013[^d^](#jso24104-note-0006){ref-type="fn"}          21 (19.4)    22 (20.4)    30 (27.8)    35 (32.4)   0.009[^d^](#jso24104-note-0006){ref-type="fn"}
                                       Distal                       207 (65.7)      65           (45--80)                             114 (55.1)                                              93 (44.9)                 57 (27.5)                                               57 (27.5)    49 (23.7)    44 (21.3)                
  T‐category                           315                          T1a/b           25 (7.9)     78            (57--88)               0.506[^a^](#jso24104-note-0003){ref-type="fn"}          9 (36.0)     16 (64.0)    0.251[^d^](#jso24104-note-0006){ref-type="fn"}          5 (20.0)     4 (16.0)     6 (24.0)     10 (40.0)   0.316[^d^](#jso24104-note-0006){ref-type="fn"}
                                       T2                           44 (14.0)       72           (54--83)                             19 (43.2)                                               25 (56.8)                 9 (20.5)                                                10 (22.7)    17 (38.6)    8 (18.2)                 
                                       T3                           127 (40.3)      66           (47--83)                             68 (53.5)                                               59 (46.5)                 32 (25.2)                                               36 (28.3)    28 (22.0)    31 (24.4)                
                                       T4a/b                        119 (37.8)      68           (45--84)                             61 (51.3)                                               58 (48.7)                 32 (26.9)                                               29 (24.4)    28 (23.5)    30 (25.2)                
  N‐category                           314                          N0              78 (24.8)    72            (54--86)               0.128[^a^](#jso24104-note-0003){ref-type="fn"}          30 (38.5)    48 (61.5)    0.017[^d^](#jso24104-note-0006){ref-type="fn"}          19 (24.4)    11 (14.1)    24 (30.8)    24 (30.8)   0.048[^d^](#jso24104-note-0006){ref-type="fn"}
                                       N1                           47 (15.0)       73           (47--85)                             21 (44.7)                                               26 (55.3)                 12 (25.5)                                               9 (19.1)     10 (21.3)    16 (34.0)                
                                       N2                           57 (18.2)       64           (48--84)                             32 (56.1)                                               25 (43.9)                 14 (24.6)                                               18 (31.6)    10 (17.5)    15 (26.3)                
                                       N3/a/b                       132 (42.0)      65           (48--80)                             73 (55.3)                                               59 (44.7)                 33 (25.0)                                               40 (30.3)    35 (26.5)    24 (18.2)                
  L‐category                           303                          L0              141 (46.5)   68            (47--83)               0.744[^a^](#jso24104-note-0003){ref-type="fn"}          73 (51.8)    68 (48.2)    0.491[^c^](#jso24104-note-0005){ref-type="fn"}          37 (26.2)    36 (25.5)    36 (25.5)    32 (22.7)   0.367[^d^](#jso24104-note-0006){ref-type="fn"}
                                       L1                           162 (53.5)      69           (49--84)                             77 (47.5)                                               85 (52.5)                 38 (23.5)                                               39 (24.1)    41 (25.3)    44 (27.2)                
  V‐category                           301                          V0              263 (87.4)   69            (47--83)               0.778[^a^](#jso24104-note-0003){ref-type="fn"}          131 (49.8)   132 (50.2)   1.000[^c^](#jso24104-note-0005){ref-type="fn"}          67 (25.5)    64 (24.3)    67 (25.5)    65 (24.7)   0.805[^d^](#jso24104-note-0006){ref-type="fn"}
                                       V1                           38 (12.6)       70           (54--84)                             19 (50.0)                                               19 (50.0)                 8 (21.1)                                                11 (28.9)    9 (23.7)     10 (26.3)                
  UICC Stage (7th ed.)                 310                          IA              18 (5.8)     75            (40--87)               0.024[^a^](#jso24104-note-0003){ref-type="fn"}          7 (38.9)     11 (61.1)    0.009[^d^](#jso24104-note-0006){ref-type="fn"}          5 (27.8)     2 (11.1)     5 (27.8)     6 (33.3)    0.012[^d^](#jso24104-note-0006){ref-type="fn"}
                                       IB                           21 (6.8)        74           (54--89)                             8 (38.1)                                                13 (61.9)                 4 (19.0)                                                4 (19.0)     7 (33.3)     6 (28.6)                 
                                       IIA                          42 (13.5)       73           (51--86)                             16 (38.1)                                               26 (61.9)                 10 (23.8)                                               6 (14.3)     12 (28.6)    14 (33.3)                
                                       IIB                          31 (10.0)       70           (47--84)                             16 (51.6)                                               15 (48.4)                 10 (32.3)                                               6 (19.4)     8 (25.8)     7 (22.6)                 
                                       IIIA                         44 (14.2)       66           (51--84)                             23 (52.3)                                               21 (47.7)                 8 (18.2)                                                15 (34.1)    10 (22.7)    11 (25.0)                
                                       IIIB                         52 (16.8)       69           (55--86)                             25 (48.1)                                               27 (51.9)                 11 (21.2)                                               14 (26.9)    10 (19.2)    17 (32.7)                
                                       IIIC                         43 (13.9)       69           (53--81)                             21 (48.8)                                               22 (51.2)                 8 (18.6)                                                13 (30.2)    13 (30.2)    9 (20.9)                 
                                       IV                           59 (19.0)       56           (40--73)                             38 (64.4)                                               21 (35.6)                 22 (37.3)                                               16 (27.1)    14 (23.7)    7 (11.9)                 
  LNR                                  306                          ≤0.229          153 (50.0)   73            (54--86)               0.005[^a^](#jso24104-note-0003){ref-type="fn"}          64 (41.8)    89 (58.2)    0.016[^c^](#jso24104-note-0005){ref-type="fn"}          33 (21.6)    31 (20.3)    39 (25.5)    50 (32.7)   0.008[^d^](#jso24104-note-0006){ref-type="fn"}
                                       \>0.229                      153 (50.0)      65           (45--78)                             86 (56.2)                                               67 (43.8)                 40 (26.1)                                               46 (30.1)    39 (25.5)    28 (18.3)                
  Tumor grade                          307                          G1/G2           70 (22.8)    74            (53--90)               **0.005** [^a^](#jso24104-note-0003){ref-type="fn"}     26 (37.1)    44 (62.9)    0.015[^c^](#jso24104-note-0005){ref-type="fn"}          14 (20.0)    12 (17.1)    20 (28.6)    24 (34.3)   0.020[^d^](#jso24104-note-0006){ref-type="fn"}
                                       G3/G4                        237 (77.2)      65           (46--81)                             128 (54.0)                                              109 (46.0)                62 (26.2)                                               66 (27.8)    58 (24.5)    51 (21.5)                
  Residual tumor                       302                          R0              263 (87.1)   69            (50--83)               0.528[^a^](#jso24104-note-0003){ref-type="fn"}          128 (48.7)   135 (51.3)   0.864[^c^](#jso24104-note-0005){ref-type="fn"}          62 (23.6)    66 (25.1)    70 (26.6)    65 (24.7)   0.994[^d^](#jso24104-note-0006){ref-type="fn"}
                                       R1/R2                        39 (12.9)       63           (38--86)                             20 (51.3)                                               19 (48.7)                 11 (28.2)                                               9 (23.1)     7 (17.9)     12 (30.8)                
  *Helicobacter pylori* status         266                          Negative        221 (83.1)   68            (49--83)               0.724[^a^](#jso24104-note-0003){ref-type="fn"}          113 (51.1)   108 (48.9)   0.626[^c^](#jso24104-note-0005){ref-type="fn"}          55 (24.9)    58 (26.2)    55 (24.9)    53 (24.0)   0.524[^d^](#jso24104-note-0006){ref-type="fn"}
                                       Positive                     45 (16.9)       71           (52--86)                             21 (46.7)                                               24 (53.3)                 10 (22.2)                                               11 (24.4)    11 (24.4)    13 (28.9)                
  EBV status                           308                          Negative        296 (96.1)   68            (49--84)               0.569[^a^](#jso24104-note-0003){ref-type="fn"}          150 (50.7)   146 (49.3)   0.138[^c^](#jso24104-note-0005){ref-type="fn"}          73 (24.7)    77 (26.0)    71 (24.0)    75 (25.3)   0.444[^d^](#jso24104-note-0006){ref-type="fn"}
                                       Positive                     12 (3.9)        74           (56--80)                             3 (25.0)                                                9 (75.0)                  1 (8.3)                                                 2 (16.7)     8 (66.7)     1 (8.3)                  
  MSI                                  303                          MSS             278 (91.7)   68            (50--83)               0.346[^a^](#jso24104-note-0003){ref-type="fn"}          140 (50.4)   138 (49.6)   0.211[^c^](#jso24104-note-0005){ref-type="fn"}          66 (23.7)    74 (26.6)    69 (24.8)    69 (24.8)   0.360[^d^](#jso24104-note-0006){ref-type="fn"}
                                       MSI‐H                        25 (8.3)        72           (63--84)                             9 (36.0)                                                16 (64.0)                 5 (20.0)                                                4 (16.0)     9 (36.0)     7 (28.0)                 
  Her2/neu status                      315                          Negative        289 (91.7)   67            (47--83)               0.011[^a^](#jso24104-note-0003){ref-type="fn"}          149 (51.6)   140 (48.4)   0.064[^c^](#jso24104-note-0005){ref-type="fn"}          74 (25.6)    75 (26.0)    70 (24.2)    70 (24.2)   0.076[^d^](#jso24104-note-0006){ref-type="fn"}
                                       Positive                     26 (8.3)        81           (66--91)                             8 (30.8)                                                18 (69.2)                 4 (15.4)                                                4 (15.4)     9 (34.6)     9 (34.6)                 
  Overall survival \[months\]          304                          Events (Dead)   243 (79.9)                                        0.274[^b^](#jso24104-note-0004){ref-type="fn"}          125 (81.2)   118 (78.7)   0.564[^e^](#jso24104-note-0007){ref-type="fn"}          63 (81.8)    62 (80.5)    60 (81.1)    58 (76.3)   0.758[^e^](#jso24104-note-0007){ref-type="fn"}
                                       Alive                        61 (20.1)                                                         29 (18.8)                                               32 (21.3)                 14 (18.2)                                               15 (19.5)    14 (18.9)    18 (23.7)                
                                       Median survival \[Months\]                                                                     14.0 ± 1.6                                              14.1 ± 1.7                15.0 ± 2.0                                              13.2 ± 2.0   13.8 ± 1.8   14.7 ± 2.5               
                                       95%CI                                                                                          10.9--17.1                                              10.7--17.4                11.1--18.8                                              9.3--17.1    10.4--17.3   9.7--19.6                
  Tumor specific survival \[months\]   281                          Events (Dead)   197 (70.1)                                        0.196[^b^](#jso24104-note-0004){ref-type="fn"}          102 (72.3)   95 (67.9)    0.370[^e^](#jso24104-note-0007){ref-type="fn"}          49 (71.0)    53 (73.6)    47 (69.1)    48 (66.7)   0.731[^e^](#jso24104-note-0007){ref-type="fn"}
                                       Alive/ DOOD                  84 (29.9)                                                         39 (27.7)                                               45 (32.1)                 20 (29.0)                                               19 (26.4)    21 (30.9)    24 (33.3)                
                                       Median survival \[Months\]                                                                     16.0 ± 1.8                                              15.6 ± 2.3                16.7 ± 1.8                                              13.6 ± 2.7   15.4 ± 2.8   15.6 ± 2.1               
                                       95%CI                                                                                          12.5--19.5                                              11.2--20.1                13.1--20.2                                              8.2--18.9    9.9--20.8    8.5--24.7                

*P*‐values printed in bold denote significant correlation after Simes\' multiple testing procedure.

UICC, union internationale contre le cancer; LNR, lymph node ratio; EBV, Epstein‐Barr‐virus; MSI, microsatellite instability; DOOD, died of other disease.

Kruskal‐Wallis test.

Cox regression. HR(Overall survival)=0.997 \[0.991‐1.002\]; HR(Tumor specific survival)=0.996 \[0.990--1.002\].

Fisher\'s exact test.

Kendall\'s tau test.

log‐rank test.
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Ki67 Expression Patterns in WTS {#jso24104-sec-0015}
-------------------------------

In WTS, three different Ki67 expression patterns could be observed: 132 cases (41.9%) showed a homogeneous or "diffuse" distribution of Ki67‐positive tumor cells; 66 cases (20.9%) showed a heterogeneous Ki67‐expression pattern with more abundant Ki67‐positive tumor cells at the tumor surface and/or at the invasion front; and 117 cases (37.1%) showed a heterogeneous, "clonal" distribution of Ki67‐positive tumor cells (Fig. [1](#jso24104-fig-0001){ref-type="fig"}). According to Laurén, a "homogeneous/diffuse" expression pattern was observed significantly more often in the unclassified phenotype, a "heterogeneous/superficial ± invasion front" distribution significantly more often in the diffuse and mixed phenotype, and a "heterogeneous/clonal" expression pattern significantly more often in the intestinal and mixed phenotype (*P* \< 0.001; Table [II](#jso24104-tbl-0002){ref-type="table-wrap"}).

![Ki67 shows a heterogeneous expression pattern in the majority of gastric cancers. (**a--c**) shows a case with an increased Ki67 expression at the tumor surface (**b**), whereas deep‐lying areas show a low Ki67 PI (**c**). (**d**) illustrates a gastric carcinoma with a heterogeneous, "clonal" Ki67 expression pattern, characterized by tumor areas with a very high Ki67 PI (right) that are located in close proximity to tumor portions with a very low Ki67 PI (left). (**e**) and (**f**) are taken from the WTS (**e**) respectively the TMA (**f**) of the same tumor that shows a homogeneous, "diffuse" distribution of Ki67 positive tumor cells and, accordingly, a good level of agreement between the Ki67 PI evaluated on WTS and TMAs. Ki67 immunostaining, original magnification 50‐fold (**a**), 250‐fold (**b**--**f**).](JSO-113-46-g001){#jso24104-fig-0001}

###### 

Correlation Between the Laurén Phenotype and Ki67 Expression Patterns

                                                       Ki67 expression pattern                           
  ------------------ ----- -------------- ------------ ------------------------- ----------- ----------- --------------------------------------------------
  Laurén phenotype   315   Intestinal     170 (54.0)   62 (36.5)                 30 (17.6)   78 (45.9)   \<0.001[^a^](#jso24104-note-0008){ref-type="fn"}
                           Diffuse        82 (26.0)    40 (48.8)                 21 (25.6)   21 (25.6)   
                           Mixed          23 (7.3)     3 (13.0)                  8 (34.8)    12 (52.2)   
                           Unclassified   40 (12.7)    27 (67.5)                 7 (17.5)    6 (15.0)    

Fisher\'s exact test.

© 2015 Wiley Periodicals, Inc.

Ki67 Pi in WTS and TMAs {#jso24104-sec-0016}
-----------------------

The Ki67 PI assessed by WTS ranged from 2% to 99% (mean 64.3%, median 69.0%, standard deviation 22.4%). Divided by the median, 157 cases (49.8%) were classified as "Ki67 low," and 158 cases (50.2%) were classified as "Ki67 high." The first quartile contained 78 cases (24.7%), the second, third, and fourth quartile contained each 79 cases (each 25.1%).

The Ki67 PI assessed by TMAs ranged from 1% to 99% (mean 47.4%, median 44.5%, standard deviation 26.6%). Divided by the Ki67 PI median evaluated on WTS, 231 cases (73.3%) were classified as "Ki67 low," and 84 cases (26.7%) were classified as "Ki67 high."

Spearman\'s rho implied a positive agreement between the WTS‐ and TMA‐Ki67 PI (r­~s~= 0.615; Fig. [2](#jso24104-fig-0002){ref-type="fig"}). Split by the median, both groups showed a moderate measure of agreement \[κ = 0.455; asymptomatic standard error (ASE) 0.044\].

![Agreement between the Ki67 proliferation index evaluated on WTS and on TMAs. Correlation between the Ki67 proliferation index (Ki67 PI) evaluated on WTS and on TMAs for the entire cohort (**a**, **b**). Both groups showed a moderate measure of agreement (κ = 0.455; **b**). The Ki67 PI in our cohort did not correlate with the sample age of WTS (blue) or TMAs (green) (**c**). There was no significant correlation between the Ki67 PI and overall patient survival (*P *= 0.564; **d**).](JSO-113-46-g002){#jso24104-fig-0002}

Regarding the Laurén phenotype, the level of agreement was moderate for intestinal (κ = 0.457; ASE 0.057), diffuse (κ = 0.412; ASE 0.106) and unclassified GCs (κ = 0.450; ASE 0.137), and fair for mixed type GCs (κ = 0.279; ASE 0.130).

Evaluating the correlation between the Ki67 expression pattern and the level of agreement of the Ki67 PI in WTS and TMAs, carcinomas with a "homogeneous/diffuse" Ki67 expression pattern showed a good level of agreement (κ = 0.673; ASE 0.064), whereas tumors with a heterogeneous Ki67 expression pattern showed a fair level of agreement (Ki67‐positive cells superficial and/or at invasion front: κ = 0.367, ASE 0.104; "clonal" expression: κ = 0.296, ASE 0.061; Supplemental File S1).

In view of the moderate agreement between TMA and WTS, we carried out all subsequent analyses using WTS only.

Evaluation of Intralaboratory Variability {#jso24104-sec-0017}
-----------------------------------------

Next we assessed the putative influence of sample age on the amount of Ki67‐positive tumor cells in WTS and TMAs. Using Spearman\'s rho, no significant agreement between the sample age and the Ki67 PI in WTS (r~s~= 0.058, *P *= 0.302) or TMAs (r~s~= 0.202, *P *= 0.127) was found (Fig. [2](#jso24104-fig-0002){ref-type="fig"}).

Clinico‐Pathological Correlation {#jso24104-sec-0018}
--------------------------------

Ki67 raw values evaluated on WTS were correlated with clinico‐pathological patient characteristics. Moreover, the Ki67 PI was split by the median, and all cases were divided accordingly into "Ki67 low" (\<median) and "Ki67 high" (≥median); additionally, the Ki67 PI was divided into quartiles. Ki67 correlated significantly with various clinico‐pathological patient characteristics (complete data is shown in Table [I](#jso24104-tbl-0001){ref-type="table-wrap"} and in Supplemental File S2). After Simes\' multiple testing procedure, the Laurén‐phenotype and the tumor grade remained the only clinico‐pathological parameter which correlated significantly with the Ki67 PI: The Ki67 PI was significantly higher in intestinal‐ and mixed‐type GCs compared to unclassified and diffuse‐type GCs (*P* \< 0.001 for raw and dichotomized Ki67 values). Moreover, the median Ki67 PI (raw value) was significantly higher in G1/G2 differentiated GCs, compared to G3/G4 GCs (74% vs. 65%, *P *= 0.005). There was no other significant correlation between the Ki67 PI and any other clinico‐pathological patient characteristic after Simes\' multiple testing procedure.

Prognostic Significance {#jso24104-sec-0019}
-----------------------

Patient prognosis significantly depended on the Laurén phenotype, tumor grade, T‐, N‐, L‐, and V‐category, LNR, as well as UICC‐stage, residual tumor status, and MSI status (Supplemental File S3). There was no significant correlation between the Ki67 status and overall (*P *= 0.564) or tumor specific patient survival (*P *= 0.370; Fig. [2](#jso24104-fig-0002){ref-type="fig"}).

Subgroup Analysis {#jso24104-sec-0020}
-----------------

The subgroup analysis of intestinal‐ and diffuse‐type GCs revealed that patients with an intestinal‐type GC and 0--2 lymph node metastases (N0‐/N1‐category) respectively a LNR \<0.229 had a significant higher median Ki67 PI than patients with ≥3 lymph node metastases (N2‐/N3‐category; *P *= 0.029) respectively a LNR ≥0.229 (*P *= 0.009). Additionally, a higher median Ki67 was observed significantly more often in UICC‐stage I and II intestinal‐type GCs compared to UICC‐stage III and IV intestinal‐type GCs (*P *= 0.007). Moreover, patients with a diffuse‐type GC and a Her2/neu‐overexpression/amplification had a significant higher median Ki67 PI compared to Her2/neu‐negative diffuse‐type GCs (82.0% vs. 52.6%; *P *= 0.036). However, in the subgroup analysis of intestinal‐ and diffuse‐type GCs, the Ki67 PI did not correlate significantly with any of the tested clinico‐pathological parameters nor with patient survival after Simes\' multiple testing procedure (data not shown).

DISCUSSION {#jso24104-sec-0021}
==========

Gastric cancer is a prevalent, aggressive, and heterogeneous disease with a poor prognosis [17](#jso24104-bib-0017){ref-type="ref"}; its distinct genetic complexity has been recently shown in an integrative genomic analysis including whole‐genome sequencing. A molecular classification of GC was proposed, which categorizes four subtypes: Epstein‐Barr‐virus (EBV)‐positive, microsatellite instable (MSI), chromosomal instable, and genomically stable GCs [18](#jso24104-bib-0018){ref-type="ref"}, [19](#jso24104-bib-0019){ref-type="ref"}. Additionally, evidence has accumulated indicating that patient prognosis and treatment‐response depends not only on the UICC tumor stage, but also on the expression and tumor specific alterations of intracellular signaling pathways [20](#jso24104-bib-0020){ref-type="ref"}. However, with regard to patient management, risk stratification is a major issue and various assays have been exploited in many different types of cancer, including gene expression profiling and counting mitoses. With regard to GC, except for TNM‐classification and the assessment of LNR, no other tissue based marker has stood the test of time or reached clinical practice.

One of the oldest, most widely and sometimes most uncritically used, tissue based marker of prognosis is Ki67. Firstly, reported in 1983 and named after its city of origin (Kiel, Germany) and the number of the original clone in the 96‐well plate, the Ki67 antibody recognizes a nuclear antigen present in proliferating cells, which is absent in resting cells [21](#jso24104-bib-0021){ref-type="ref"}. Since then and despite great efforts, Ki67 could be established only in a minority of cancer entities because it often led to inconsistent and disappointing results. This also applies to GC. Ki67 has been tested as a prognostic biomarker in GC several times during the last decades, but the results remained contradictory: Several authors described a correlation between a *high* Ki67 PI and a poor prognosis, whereas Lee et al. [22](#jso24104-bib-0022){ref-type="ref"} associated a *low* Ki67 PI with a poor patient\'s outcome; still other authors declared that Ki67 is of no prognostic value at all. These discrepancies might be related to methodological issues: The number of patients studied in 13 former studies ranged from 43 to 418. Apart from one single study, all other larger series relied on the analysis of TMAs, without ever testing whether this is a reliable approach to assess the Ki67 PI in GC at all. The number of cells counted in a single tumor ranged by a factor of ten from 100 to 1,000 or was sometimes not even indicated. Moreover, the cut‐off value to determine "Ki67 high" seemed to be chosen arbitrarily in most studies (Table [III](#jso24104-tbl-0003){ref-type="table-wrap"}) [5](#jso24104-bib-0005){ref-type="ref"}, [22](#jso24104-bib-0022){ref-type="ref"}, [23](#jso24104-bib-0023){ref-type="ref"}, [24](#jso24104-bib-0024){ref-type="ref"}, [25](#jso24104-bib-0025){ref-type="ref"}, [26](#jso24104-bib-0026){ref-type="ref"}, [27](#jso24104-bib-0027){ref-type="ref"}, [28](#jso24104-bib-0028){ref-type="ref"}, [29](#jso24104-bib-0029){ref-type="ref"}, [30](#jso24104-bib-0030){ref-type="ref"}, [31](#jso24104-bib-0031){ref-type="ref"}, [32](#jso24104-bib-0032){ref-type="ref"}, [33](#jso24104-bib-0033){ref-type="ref"}.

###### 

Literature Review

  Reference           Publication date   n     Sample material   Cells counted   Mean %   Median %   Cut‐off                                            Correlation with clinco‐pathological parameters                                                                                    Correlation with survival
  ------------------- ------------------ ----- ----------------- --------------- -------- ---------- -------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------
  Müller et al.       1996               418   WTS               1000            51.3     53.3       Median                                             None                                                                                                                               None
  Ramires et al.      1997               43    WTS               1000            32.7     n.s.       n.s.                                               None                                                                                                                               n.e.
  Manzoni et al.      1998               56    WTS               1000            n.s.     n.s.       \<10%, 10--40%, \>40%                              Higher Ki67 PI in patients \>68 years                                                                                              High Ki67 PI correlates with poor prognosisin patients \>68 years
  Oshima et al.       2005               70    WTS               1000            n.s.     n.s.       40%                                                None                                                                                                                               None
  Czyzewska et al.    2009               100   WTS               10 HPF          n.s.     n.s.       50%                                                High Ki67 PI in pT3/4 respectively pN2 tumors                                                                                      None
  Tsamandas et al.    2009               110   WTS               500             25.3     30.0       Median                                             High Ki67 PI in G3/G4 tumors                                                                                                       High Ki67 PI correlates with poor prognosis
  Lee et al.          2010               245   TMA               300             23.1     15.7       0--10%, 11--20%, 21--30%. 31--40%,41--50%, \>50%   High Ki67 in G1/G2, pT1/2, pN0 tumors                                                                                              High Ki67 correlates with good prognosis
  Lazar et al.        2010               67    WTS               500             46.2     n.s.       45%                                                High Ki67 in patients \>60 years, cardia tumors, papillary adenocarcinoma, G3 tumors                                               None
  He et al.           2012               166   TMA               1000            n.s.     n.s.       0--4%, 5--25%, 26--50%, \>50%                      n.e.                                                                                                                               High Ki67 PI correlates with poor prognosis
  Kroepil et al.      2013               163   TMA               n.s.            n.s.     7          Median                                             None                                                                                                                               n.e.
  Xiao et al.         2013               413   TMA               100             n.s.     n.s.       0%, 1--50%, 50--74%, 75--100%                      High Ki67 in UICC stage I tumors                                                                                                   None
  Wu et al.           2014               101   WTS               n.s.            n.s.     n.s.       0--10%, 11--50%, 51--75%, \>75%                    High Ki67 in poorly differentiate tumors, tumors with lymph node metastasis, UICC stage III‐/IV‐tumors, Her2/neu‐positive tumors   n.e.
  Saricanbaz et al.   2014               50    WTS               n.s.            n.s.     n.s.       0--5%, 6--30%, 30--60%, 61--100%                   None                                                                                                                               None

WTS, whole tissue sections; TMA, tissue microarray; n.s., not specified; n.e., not evaluated.

© 2015 Wiley Periodicals, Inc.

Thus, the vast majority of former studies, which have investigated the significance of Ki67 PI in GC might have been biased by methodological issues. In the present study, we intended to circumvent this problem and explored for the first time systematically the value of TMAs for the assessment of KI67 PI in GC by comparing staining with WTS obtained from the same paraffin blocks.

With regard to Ki67 scoring standardization, it is generally difficult to determine a single useful cut‐off point: Firstly, Ki67 displays a continuous distribution; secondly, Ki67 is highly capable of being influenced by pre‐analytical and analytical variables. In breast cancer, where Ki67 is routinely used as a part of a multi‐parameter prognostic biomarker, substantial variability in Ki67 scoring is known to be present among some of the world\'s most experienced laboratories. As a consequence, Ki67 values and cut‐offs cannot be transferred between different laboratories without standardizing scoring methodology [34](#jso24104-bib-0034){ref-type="ref"}, [35](#jso24104-bib-0035){ref-type="ref"}. It is recommended that Ki67 scores should be interpreted in the light of local laboratory values, instead of suggesting a universally valid cut‐off value [36](#jso24104-bib-0036){ref-type="ref"}. Consequently, we abstained from applying defined cut‐off values as previously done in many other studies, and chose an evaluation of the raw Ki67 values and additionally a separation by the median and into quartiles instead, as this is the most reliable way to consider interlaboratory variability.

Ki67 Is a Potential Indicator of Intratumoral Heterogeneity {#jso24104-sec-0022}
-----------------------------------------------------------

Intratumoral genetic and phenotypic heterogeneity is another major risk for sampling errors, as smaller tissue samples, for example, biopsies, bear the risk of being not representative for the entire tumor mass. Although, it is well known in GC, for example, in the evaluation of the Her2/neu status, it is widely neglected in most biomarker studies [15](#jso24104-bib-0015){ref-type="ref"}, [37](#jso24104-bib-0037){ref-type="ref"}. Heterogeneity may not solely be present among cases of a particular tumor type, but also within an individual cancer with subclones that might response variably to anti‐cancer drugs. Thus, biomarkers with the ability to indicate intratumoral heterogeneity are urgently needed. Interestingly, Ramires et al. already described distinct intratumoral Ki67 expression patterns in GC that correlated significantly with the Laurén phenotype. They observed that subgroups of GCs showed an increased Ki67 expression within the tumor surface compared to deeper tumor areas, and vice versa. Moreover, a "focal clustering" was also described in a subset of GCs [23](#jso24104-bib-0023){ref-type="ref"}. In addition to these previous findings, we noticed that three distinct Ki67 expression patterns are present in GC, and that two of them showed a heterogeneous Ki67‐expression pattern that might indicate intratumoral heterogeneity.

TMAs Are Unsuitable for the Ki67 PI Evaluation in GC {#jso24104-sec-0023}
----------------------------------------------------

In our patient series, only the minority of GCs showed an even, homogeneous intratumoral distribution of Ki67‐positive tumor cells. We made similar observations with regard to heterogeneous expression of HER2 and MET in GC and came to the conclusion that TMAs, like any other tissue biopsy, carry the risk of a sampling error [15](#jso24104-bib-0015){ref-type="ref"}, [38](#jso24104-bib-0038){ref-type="ref"}. This risk is exemplified by: (i) the fact that the mean Ki67 PI evaluated on TMAs underestimated the Ki67 PI by 16.9%; and (ii) the moderate level of agreement between TMA and WTS, which raised to a good level of agreement if those tumors with a "homogeneous/diffuse" Ki67 expression pattern were evaluated separately. These findings lead to the conjecture that studies using TMAs only, carry the risk of a sampling error due to a non‐representative evaluation and systematic underestimation of the Ki67 PI in GC.

The Ki67 PI Does Not Depend on Sample Age {#jso24104-sec-0024}
-----------------------------------------

Collecting sufficient patient numbers is time consuming, and storage of paraffin blocks and changes in pre‐analytical procedures may lead to antigen degradation/modification influencing test results [39](#jso24104-bib-0039){ref-type="ref"}. The tissue samples of our study were collected over a period of 12 years and had been stored between 6 and 18 years prior to study execution. However, in our series no correlation was found between sample age and neither quantity nor intensity of Ki67 immunostaining, neither for WTS nor for TMAs. Thus, sample age does not influence the test result of the KI67 PI.

The Ki67 PI Is Correlated Significantly With the Laurén Phenotype and Tumor Grade, But Has No Prognostic Value in GC {#jso24104-sec-0025}
--------------------------------------------------------------------------------------------------------------------

The conclusion that a high amount of proliferating tumor cells indicates a fast growing tumor with an increased potential to metastasize and a worse prognosis has been recently discussed controversially [40](#jso24104-bib-0040){ref-type="ref"}. Contradictory to most previous studies, Lee et al. stated that highly proliferative tumors possess less invasive subclones and thus, have a less aggressive metastatic potential that results in a better patient prognosis [22](#jso24104-bib-0022){ref-type="ref"}. Nevertheless, Lee\'s findings are compromised by their use of TMAs and thereby may have missed intratumoral heterogeneity of GC. Neither previous finding, that is, positive or negative prediction of patient prognosis, could be confirmed in our cohort.

Interestingly, the Ki67 PI correlated with the Laurén phenotype and the tumor grade, and a significant correlation between the distinct expression patterns and the Laurén phenotype was also observed. The molecular classification of GC [18](#jso24104-bib-0018){ref-type="ref"} also correlates to some extent with the Laurén phenotype: Genomically stable GCs were enriched in the diffuse type GC, which also showed most commonly a homogeneous Ki67 PI in our cohort. The chromosomal instable GCs were more commonly associated with an intestinal phenotype, which in our analysis most frequently harbored a heterogeneous/clonal Ki67 distribution. Chromosomal instable GCs often show amplification of receptor tyrosine kinases and our previous studies on the same cohort confirmed the occurrence of intratumoral heterogeneity with *HER2* or *MET*‐amplified and unamplified tumor cell clones, respectively, within the same patient [15](#jso24104-bib-0015){ref-type="ref"}, [38](#jso24104-bib-0038){ref-type="ref"}. Thus, Ki67 PI in GC may be linked to the Laurén phenotype based on molecular biological differences (genomically stable vs. genomically instable) rather than indicators of patient prognosis. Indeed, Ki67 PI assessed on WTS did not correlate with patient survival at all in our series, neither for the entire cohort nor for the subgroup analysis of intestinal‐ and diffuse‐type GCs.

While interpreting our findings, it should be kept in mind that the proliferation rate of a tumor is a temporal snap‐shot and may provide no information about the history or future development of the individual cancer. In future studies, the presence of the three distinct Ki67 expression patterns needs to be correlated with other indicators of intratumoral heterogeneity, especially molecular characteristics.

Summing up, the present study is the first that considers (and eliminates) the risks of sampling errors when using TMAs (or biopsies) of GCs. The assessment of Ki67 in archival tissue samples is not influenced by intralaboratory pre‐analytical variables (e.g., storage time) and is unsuitable as a prognostic biomarker for GC. However, Ki67 may unravel tumor heterogeneity, and future studies should pay special attention to a standardized evaluation and appropriate and representative tissue sampling.
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**File S1**. Correlation of Ki67 in tissue microarrays (TMAs) and whole tissue sections (WTS) within the different expression patterns. The application of TMAs bears the risk of a systematic underestimation of the Ki67 PI, which is moderate in tumors with and homogenous/"diffuse" Ki67 expression pattern (a) but especially high in tumors with a heterogeneous expression pattern with an increased Ki67 at the tumor surface and/or the invasion front (b) respectively tumors with an heterogeneous/"clonal" Ki67 expression pattern (c).
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Click here for additional data file.
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**File S2**. Box‐plots illustrate the distribution of the Ki67 PI within the subgroups of the 17 tested clinico‐pathological patient characteristics.
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Click here for additional data file.
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**File S3**.Correlation between clinico‐pathological patient characteristics and overall as well as tumor specific patient survival.
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Click here for additional data file.
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